Manoj K: How Incyte Could Help Transform Care for Patients With von Willebrand Disease
Manoj K, Senior Partner and Life Sciences Industry Leader at IBM Consulting, shared a post on LinkedIn:
“Twice a week. Every week. For life. That has been the burden for patients with von Willebrand disease (VWD), the most common inherited bleeding disorder more prevalent than hemophilia A and B combined.
While hemophilia advanced with gene therapies and extended factors, VWD patients relied on frequent IV plasma-derived concentrates, unchanged since the 1980s. That changed with today’s news.
Incyte is nearing a deal to acquire Star Therapeutics for up to $2B ($1.25B upfront plus $750M milestones). The prize: VGA039, a first-in-class once-monthly subcutaneous monoclonal antibody self-administered at home, no IV, no hospital.
At the center of the deal is VGA039 Star’s first-in-class monoclonal antibody targeting Protein S, currently in pivotal Phase 3 trials for von Willebrand disease.
The therapy, known as VGA039, is in late-stage clinical testing and has received Fast Track designation from the U.S. FDA. For Incyte, this is the hematology anchor their post-Jakafi pipeline has been missing.
The human stakes are straightforward. Today’s VWD patients endure two to three IV infusions every week hospital-dependent, schedule-disrupting, relentless.
VGA039 replaces that entirely with a once-monthly subcutaneous injection, self-administered at home. Same protection. A fraction of the burden.
The acquisition would also mark the first major deal under Incyte CEO Bill Meury, who took over last year and has emphasized acquisitions as a way to offset future revenue pressure from the expected 2028 patent expiration of the company’s top-selling blood cancer drug, Jakafi.
Star Therapeutics backed by Sofinnova Partners, RA Capital Management, and Catalio Capital Management had explored an IPO before the math of a strategic sale proved more compelling.
Incyte‘s expertise in blood disorders could help position the company to commercialize VGA039 if it wins regulatory approval.”
Stay updated with Hemostasis Today.
-
Sep 20, 2026, 05:17Maxime Dely: When ABO Compatibility Isn’t Enough for Safe Transfusion
-
Sep 20, 2026, 04:54William Aird: What Does a Complete History and Physical Really Mean?
-
Sep 20, 2026, 04:34Hons Saurabh Kaushik: Why Uncontrolled LDL Can Be Harmful
-
Sep 20, 2026, 03:58Salih Ehsan: The Complexities of HbF and HbA2
-
Sep 20, 2026, 03:22The Voices of People Living With Bleeding Disorders – EHC
-
Sep 20, 2026, 01:18Sebastian Mafeld: Has 2026 Changed How We Treat Pulmonary Embolism?
-
Sep 20, 2026, 01:16Pall T. Onundarson: DOACs – Monitoring, Tailoring Dose and Identifying Problems
-
Sep 20, 2026, 01:15Thierry Fumeaux: From Efficacy to Effectiveness – The Value of Real-World Evidence
-
Sep 20, 2026, 01:14Said El Shamieh: VEGFA Genetic Variants and Bleeding Risk During Warfarin Therapy